Screener
Corcept Therapeutics CORT Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | 256,147 | 194,430 | 421,050 | 351,644 |
| Operating expenses: | ||||
| Cost of sales | 4,061 | 3,433 | 6,944 | 5,836 |
| Research and development | 53,890 | 60,471 | 120,155 | 121,206 |
| Selling, general and administrative | 156,896 | 103,851 | 302,252 | 194,511 |
| Total operating expenses | 214,847 | 167,755 | 429,351 | 321,553 |
| Income (loss) from operations | 41,300 | 26,675 | (8,301) | 30,091 |
| Interest and other income | 4,631 | 5,017 | 9,517 | 11,219 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total revenue?
- Corcept Therapeutics (CORT) reported total revenue of $256.15M in Q2 2026.
- How has Corcept Therapeutics's total revenue changed year-over-year?
- Corcept Therapeutics's total revenue increased by 31.7% year-over-year, from $194.43M to $256.15M.
- What is the long-term trend for Corcept Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Corcept Therapeutics's total revenue has grown at a 20.1% compound annual growth rate (CAGR), from $365.98M to $761.41M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Corcept Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude